Skip to main content
. 2024 Feb 8;20:59–73. doi: 10.2147/TCRM.S434556

Table 2.

Prevalence, Method, and Outcome of FLT3 Mutation Testing for Patients with AML

Key Epidemiologic Characteristic, n (%) All ND AML Patients N = 853 All R/R AML Patients N = 289
Progression from ND to R/R AML 289 (33.9)
 Relapsed after initial treatment 234 (27.4)
 Refractory to initial treatment 55 (6.4)
FLT3 mutation testing
 At initial AML diagnosis 541 (63.4)
 At first R/R diagnosis 72 (24.9)
 NGS testing method 541 (100) 72 (100)
 Other testing method 0 0
FLT3MUT positivity among tested patientsa
 At initial AML diagnosis 109 (20.1)
  FLT3-ITD mutation 53 (48.6)
  FLT3-TKD mutation 32 (29.4)
  Unspecified FLT3 mutation 26 (23.9)
 At first R/R AML diagnosis 14 (19.4)
  FLT3-ITD mutation 9 (64.3)
  FLT3-TKD mutation 6 (42.9)
  Unspecified FLT3 mutation 1 (7.1)
FLT3 testing at both initial AML and first R/R diagnoses 54 (18.7)
 Lost FLT3 mutation at first R/R 3 (5.6)
 Gained FLT3 mutation at first R/R 5 (9.3)
FLT3-ITD vs FLT3-TKD mutation switch at first R/R 3 (5.6)
  From FLT3-ITD to FLT3-TKD 1 (33.3)
  From FLT3-TKD to FLT3-ITD 2 (66.7)

Notes: aPatients could harbor both FLT3-ITD and FLT3-TKD mutations, therefore, the percentages of each FLT3 mutation type may not add up to 100%.

Abbreviations: AML, acute myeloid leukemia; FLT3, FMS-like tyrosine kinase-3; ITD, internal tandem duplication; MUT, mutated; ND, newly diagnosed; NGS, next generation sequencing; R/R, relapsed or refractory; TKD, tyrosine kinase domain.